Research Analysts Offer Predictions for Valneva Q3 Earnings

Valneva SE Sponsored ADR (NASDAQ:VALN) – Research analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for shares of Valneva in a research note issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.18) per share for the quarter, up from their previous estimate of ($0.19). The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s FY2026 earnings at ($0.81) EPS, FY2027 earnings at $1.82 EPS, FY2028 earnings at $1.80 EPS and FY2029 earnings at $2.05 EPS.

Separately, Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Valneva Price Performance

Shares of VALN opened at $10.32 on Monday. The company has a current ratio of 2.38, a quick ratio of 1.85 and a debt-to-equity ratio of 1.52. The company’s fifty day simple moving average is $10.29 and its 200 day simple moving average is $9.69. Valneva has a 1-year low of $5.43 and a 1-year high of $12.25. The company has a market cap of $888.66 million, a price-to-earnings ratio of -6.53 and a beta of 1.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. VSM Wealth Advisory LLC lifted its position in Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Valneva in the fourth quarter valued at approximately $44,000. JPMorgan Chase & Co. acquired a new position in shares of Valneva in the third quarter valued at approximately $124,000. XTX Topco Ltd bought a new position in shares of Valneva during the fourth quarter worth approximately $94,000. Finally, Marex Group plc bought a new position in shares of Valneva during the second quarter worth approximately $64,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.